Tamiflu Safety Will Get FDA Committee Review Nov. 27
This article was originally published in The Pink Sheet Daily
Executive Summary
The Pediatric Advisory Committee will evaluate reported neuropsychiatric and behavioral events from patients taking Roche’s influenza product.
You may also be interested in...
Tamiflu U.S. Labeling Adopts Japanese Warnings
Neuropsychiatric adverse event reports for Roche's antiviral jump in most recent review, prompting FDA staff to suggest a labeling change.
Tamiflu Cleared For Pediatric Flu Prevention
Roche's antiviral oseltamivir is now approved for treatment and prevention of influenza in children, adolescents and adults.
Tamiflu Adverse Event One Year Update Requested By Advisory Committee
Pediatric Advisory Committee agrees with FDA that neuropsychiatric events and deaths seen in pediatric patients receiving the antiviral do not represent risk signals.